Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years

Should Novo Nordisk and Eli Lilly investors be worried about Roche? Novo Nordisk (NVO -1.58%) and Eli Lilly (LLY -1.01%) are the top two companies in the weight loss market right now. They are both raking in billions in revenue from their glucagon-like peptide-1 (GLP-1) drugs. But given how lucrative the market is -- one estimate says it will be worth $100 billion by 2030 -- you can be sure that there will be a lot of competition. In fact, several small, up-and-coming healthcare companies are developing GLP ...